Theradaptive, Inc.

Theradaptive was founded to give patients who have no good options a better choice. Through our protein engineering platform, we can "paint" therapeutic molecules onto implants to deliver localized, sustained therapy where it is needed the most while eliminating detrimental side effects that would come from systemic delivery. Our first products address the spinal fusion and dental defect markets, but we are also expanding into oncology as well, addressing a total market size of over $100B+.
As a spinout from MIT, we have raised $40M to date, including $20M from Department of Defense funding and are seeking to raise $50-$100M for a Series B round. We have received 3 breakthrough device designations from the FDA and expect to launch our first product at the end of 2025 with human clinical trials beginning in late 2023.